Clicky

aTyr Pharma, Inc.(LIFE)

Description: aTyr Pharma, Inc. engages in the discovery and clinical development of protein based therapeutics for patients suffering from severe and rare diseases. The company is developing Resolaris, which is in Phase Ib/II clinical trials in adult patients with facioscapulohumeral muscular dystrophy, a rare genetic myopathy with an immune component. Its products pipeline also includes Resolaris for treatment of patients with early onset facioscapulohumeral muscular dystrophy, a rare genetic myopathy with an immune component and limb-girdle muscular dystrophies, as well as rare pulmonary diseases with an immune component. In addition, the company is developing iMod.Fc, a preclinical immuno-modulatory domain program. The company was founded in 2005 and is headquartered in San Diego, California.


Keywords: Organ Systems Rare Diseases Clinical Development Dystrophy Pulmonary Disease Muscular Dystrophy Musculoskeletal System Myopathy Severe And Rare Diseases Facioscapulohumeral Muscular Dystrophy Muscular Dystrophies Atyr Pharma Limb Girdle Muscular Dystrophies

Home Page: www.atyrpharma.com

LIFE Technical Analysis

3545 John Hopkins Court
San Diego, CA 92121
United States
Phone: 858 731 8389


Officers

Name Title
Dr. Sanjay S. Shukla M.D., M.S. Pres, CEO & Director
Ms. Jill M. Broadfoot Chief Financial Officer
Ms. Nancy E. Denyes Krueger Gen. Counsel & Corp. Sec.
Xiang-Lei Yang Ph.D. Founder
Ms. Ashlee Dunston Director of Investor Relations & Corp. Communications
Mr. Peter Villiger VP of Corp. Devel.
Ms. Danielle Campbell VP of Human Resource
Dr. Leslie Nangle Ph.D. VP of Research
Dr. Ying J. Buechler Ph.D. Exec. Director of Biologics Devel. & Manufacturing
Dr. Melissa A. Ashlock Sr. Advisor

Exchange: NASDAQ

Country: US

Currency: US Dollar ($)

Forward PE: 0
Trailing PE: 0
Price-to-Book MRQ: 0.8306
Price-to-Sales TTM: 37.7611
IPO Date: 2015-05-07
Fiscal Year End: December
Full Time Employees: 49
Back to stocks